Correlated with this decrease in GSH levels, we found that the T2DM group also has significantly higher levels of MDA ( Figures 3B, C ) and higher levels of the proinflammatory cytokine IL-6 ( Figure 3D ) than the healthy group
This means side effects are possible, especially at high doses, with long-term use, or in vulnerable populations
Roche Oral SM Late Entrant Roche (RO7795068) is running two pivotal Phase 3 trials (ENITH-1: obesity without T2D
Beyond Individual Choice The Danish study utilized nationwide health registries to track every adult who started semaglutide for weight loss between its December 2022 launch and October 2023
GLP-1 receptor agonists mimic GLP-1 to treat type 2 diabetes
Reflux, nausea, or abdominal symptoms that worsen after dose escalation and do not improve with basic plan changes